Generic Name and Formulations:
Niacin 500mg, 750mg, 1g; ext-rel tabs.
Indications for NIASPAN:
Adjunct to diet in primary hyperlipidemia and mixed dyslipidemia to reduce elevated total-C, LDL-C, apo B, TG and to increase HDL-C. To reduce risk of recurrent nonfatal MI in patients with a history of MI and hyperlipidemia. Combined with a bile acid sequestrant to slow progression or promote regression of atherosclerosis in patients with coronary artery disease and hyperlipidemia. Combined with a bile acid sequestrant to reduce elevated total-C and LDL-C in primary hyperlipidemia when diet or diet + monotherapy has been inadequate. Adjunct in patients with severe hypertriglyceridemia who are at risk for pancreatitis, when determined dietary measures are inadequate.
Limitations Of use:
The addition of Niaspan did not reduce cardiovascular morbidity or mortality among patients treated with simvastatin in a controlled trial.
Swallow whole. Take at bedtime with low-fat snack. Avoid concomitant alcohol, hot beverages, or spicy foods; may pre-treat with aspirin (up to 325mg) ½ hour before dosing. >16yrs: initially 500mg once daily for 4 weeks, then 1g once daily for weeks 5–8. May increase by up to 500mg every 4 weeks to usual range of 1–2g daily; max 2g/day. Retitrate if restarting after an extended time. Women may respond at lower doses than men.
≤16yrs: not established.
Active liver disease. Unexplained elevations of serum transaminases. Active peptic ulcer disease. Arterial bleeding.
Do not substitute for equivalent doses of immediate-release or sustained-release niacin (hepatotoxicity may occur). History of jaundice, hepatobiliary disease, peptic ulcer. Substantial alcohol consumption. Monitor serum transaminase levels (before treatment, then every 6–12 weeks for 1 year, then periodically); discontinue if transaminase levels ≥3xULN persist or if signs of liver disease occur. Renal impairment. Cardiovascular disease (eg, unstable angina, acute MI). Gout. Monitor blood glucose and for hypophosphatemia. Surgery. Diabetes or patients at risk for diabetes. Uncontrolled hypothyroidism. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Nicotinic acid deriv.
Avoid other products with high amounts of niacin or nicotinamide, alcohol. Monitor for myopathy/rhabdomyolysis with HMG-CoA reductase inhibitors. May potentiate antihypertensives, other vasoactive drugs (eg, ganglionic or adrenergic blockers, nitrates, calcium channel blockers). Caution with anticoagulants (monitor PT and platelet counts). Antidiabetic agents may need adjustment. Separate dosing of bile acid sequestrants by at least 4–6 hours. May cause false (+) Benedict's test.
Flushing, diarrhea, nausea, vomiting, cough, pruritus, rash, dizziness, tachycardia, palpitations, shortness of breath, sweating, chills, edema, muscle pain; glucose intolerance, abnormal LFTs.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|